Cannabinoid observatory and product analysis

CBG in France and CBDV in Germany: what did each country authorise?

What would it take to verify a label that says “legal CBG”? For seeds of the French hemp variety Seraly 25, the answer is a dated entry in the official journal. Germany has a similarly precise record for an experimental oral solution containing a different cannabinoid, cannabidivarin. Both records identify the product, the country and the purpose covered by the decision.

Milnubes editorial desk · 14 November 2026

Potential CBG content in agricultural trials. Seraly 25, 8.30%, and Revelation, 0.29%.

Documents checked on 14 November 2026. Agronomic data are from CTPS/GEVES and reflect the conditions of its 2024 and 2025 trials.
What can be checked	Document	Scope
Seraly 25 seed · France	Order of 27 March 2026, Article 1	Ten-year listing on List A of varieties whose seed may be marketed.
Potential CBG in Seraly 25 · France	CTPS/GEVES, 2024 and 2025 trials, p. 8	8.30% in the combined trial figures. This describes the plant material evaluated.
CBDV oral solution · Germany	EudraCT 2014-005344-17, sections D and N	BfArM authorised the trial. The register records marketing authorisation separately.
CBD in e-liquids · Switzerland	Federal guide, version 8, section 5.8	The passage names CBD. It does not establish specific permission for added CBG, CBN or CBC.

How Seraly 25 found its way into the French seed catalogue

On 29 March 2026 the French official journal published the ten-year listing of Seraly 25 and Revelation on List A, the register of varieties whose seeds may be marketed in France. The agricultural trials explain their connection to cannabigerol. Across the 2024 and 2025 growing seasons, CTPS/GEVES reported a potential CBG content of 8.30% for Seraly 25 and 0.29% for Revelation. Those figures describe plant material tested under the trial conditions. A particular batch would need its own analysis.

Which product does the French listing cover?

Both varieties also appeared in the supplement to the EU common agricultural variety catalogue on 26 May 2026. In France, Article 1 of the order of 30 December 2021 sets conditions for hemp, including a maximum of 0.30% delta-9-THC for eligible varieties. Flower and leaf production requires certified seed and is reserved for active farmers. The catalogue entry settles a question about an agricultural variety. Whether a finished CBG cartridge could be sold in Spain would require a separate assessment under the rules for that product and destination.

Berlin's CBDV trial has a product code

On 26 May 2015 the German medicines authority BfArM authorised a phase II trial of the CBDV oral solution GWP42006. Researchers at Charité compared it with placebo in people with HIV-associated neuropathic pain. The trial ended on 15 January 2020. The investigators found no significant reduction in pain compared with placebo. The trial record also states that the investigational product lacked a marketing authorisation.

Does a statement about CBD cover CBG, CBN or CBC e-liquids?

Section 5.8 of Switzerland’s May 2025 federal guidance explicitly addresses adding CBD to e-cigarettes and refills. It describes this as generally permitted and sets out obligations for self-monitoring, notification and labelling. Cannabinol (CBN) and cannabichromene (CBC) are separate compounds. The passage does not document specific permission to add isolated CBN, CBC or CBG to a refill liquid. A Spanish retailer would also need evidence relevant to the product under Spanish rules.

Switzerland has a specific rule for pure CBN

In July 2026 Swissmedic clarified that pure CBN falls under group 303 of the Swiss controlled substances ordinance. There is an exemption for industrial or scientific use that can be substantiated, subject to the law governing the finished product. Private use remains controlled, and trade alone does not qualify as industrial use. The clarification separately addresses CBN occurring naturally in cannabis at its original concentration, without enrichment or addition.

What the European Commission decided about CBG in food

On 29 July 2024 the Commission closed two novel food applications, one for synthetic CBG (NF/2022/6330) and one for CBG from Cannabis sativa L. (NF/2022/6332). Neither decision added CBG to the Union list. EFSA’s safety statement of 9 February 2026 concerns CBD in certain food supplement formulations. It is a scientific assessment of oral intake. An authorisation to place a food on the market is a separate decision.